■ Corrections

Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists

Handelsman Y, Wyne K, Cannon A, Shannon M, Schneider D, *J Manag Care Spec Pharm.* 2018;24(9-a):S14-S29

In the *JMCP* September 2018 supplement “Once-Weekly GLP-1 Receptor Agonists for the Management of Type 2 Diabetes: A Review of Clinical and Health Economic Data,” body weight change data from the AWARD-6 study were presented incorrectly in the article cited above. In Figure 2B on page S20 and related narrative text on page S19, the mean changes in body weight in the AWARD-6 study should have been reported as -3.6 kg with liraglutide and -2.9 kg with dulaglutide 1.5 mg. Readers are encouraged to access the corrected version which is freely available online at: <https://www.jmcp.org/doi/pdf/10.18553/jmcp.2018.24.issue-9-a>.